Related Experiment Video
Updated: Aug 19, 2025

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
Management of Submacular Hemorrhage Using Intravitreal Brolucizumab with Pneumatic Displacement: A Case Series
Somnath Chakraborty1, Jay Umed Sheth2
1Retina Institute of Bengal, Siliguri, India.
Abstract:
The management of submacular hemorrhage (SMH) necessitates rapid clearing of the bleed for optimal visual outcomes. We present a series of 3 cases with large fresh SMH (≤7 days) secondary to MNV that were treated with intravitreal injection (IVI) of brolucizumab along with SF6 gas injection. A face-down position was recommended for 5 days after the injection, with follow-up visits at regular intervals. All eyes demonstrated notable improvement in visual acuity with complete resolution of SMH lasting up to 6 months. There were no ocular or systemic side effects. Thus, IVI brolucizumab with SF6 gas injection is efficacious and safe for the management of large SMH secondary to MNV.
Insights
Intravitreal brolucizumab with SF6 gas injection effectively clears large submacular hemorrhage (SMH) from MNV, improving vision. This safe treatment shows sustained results up to six months without side effects.
Area of Science:
- Ophthalmology
- Retinal diseases
Background:
- Submacular hemorrhage (SMH) management requires rapid bleed clearance for visual recovery.
- Macular neovascularization (MNV) is a common cause of SMH.
Related Concept Videos
Angle Closure Glaucoma: Treatment
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...

